← Back to patent-cliff list
Anagrelide Hydrochloride Hydrate
Tier C — Watch / tradeAnagrelide Hydrochloride Hydrate
Shire Pharmaceuticals
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PDE3
Brand：Anagrelide CR, Thromboreductin, Agrylin, CR anagrelide, Xagrid
Indications (approved)：Essential thrombocythaemia, Myeloproliferative neoplasm
Regional status
US
Approved
1997-03-14
EU
Approved
2004-11-15
China
Approved
2024-02-23
Japan
Approved
2014-09-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Anagrelide Hydrochloride Hydrate?
Approved indications include: Essential thrombocythaemia, Myeloproliferative neoplasm.
When does the Anagrelide Hydrochloride Hydrate patent expire?
No public expiry year is available for Anagrelide Hydrochloride Hydrate yet; this page updates once verified.
How do I get a quote for Anagrelide Hydrochloride Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27